母亲接受短程治疗后，HIV-1 感染的早产儿中拉替拉韦经胎盘转运的一个月药代动力学。
One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.
机构信息
Infectious Diseases Unit, L.C. Fleming Hospital, Saint Martin, French West Indies.
出版信息
Antimicrob Agents Chemother. 2013 Dec;57(12):6393-4. doi: 10.1128/AAC.01349-13. Epub 2013 Sep 30.
Abstract
We describe the pharmacokinetics of raltegravir of a preterm newborn after short-course treatment of the mother tested HIV + the day of delivery. At age 1 month, the circulating concentration of raltegravir in the newborn was 29 ng/ml (the IC95 of RAL against HIV-1 is 15 ng/ml). Raltegravir should therefore be considered a potential transplacental postexposure prophylaxis for HIV-1 and an alternative to the use of boosted lopinavir in this context.
摘要
我们描述了一例 HIV 阳性母亲于分娩当天接受短程治疗后，其早产儿的拉替拉韦药代动力学。1 月龄时，新生儿循环中的拉替拉韦浓度为 29ng/ml（拉替拉韦抗 HIV-1 的 IC95 为 15ng/ml）。因此，拉替拉韦应被视为 HIV-1 潜在的胎盘暴露后预防药物，可替代该背景下使用洛匹那韦利托那韦。
相似文献
1
One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.
Antimicrob Agents Chemother. 2013 Dec;57(12):6393-4. doi: 10.1128/AAC.01349-13. Epub 2013 Sep 30.
2
Raltegravir pharmacokinetics in neonates following maternal dosing.
J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316.
3
Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates.
AIDS. 2012 Nov 28;26(18):2421-3. doi: 10.1097/QAD.0b013e32835a9aeb.
4
Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study.
J Pharm Biomed Anal. 2020 Jan 5;177:112838. doi: 10.1016/j.jpba.2019.112838. Epub 2019 Aug 27.
5
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.
6
Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer.
Biomed Res Int. 2014;2014:851820. doi: 10.1155/2014/851820. Epub 2014 May 25.
7
Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
Antimicrob Agents Chemother. 2012 Apr;56(4):1892-8. doi: 10.1128/AAC.05694-11. Epub 2012 Jan 17.
8
Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing.
Antimicrob Agents Chemother. 2012 Dec;56(12):6132-6. doi: 10.1128/AAC.00942-12. Epub 2012 Sep 10.
9
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing.
CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):643-653. doi: 10.1002/psp4.12443. Epub 2019 Jul 10.
10
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18.
引用本文的文献
1
HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment.
Pharmaceuticals (Basel). 2022 Dec 9;15(12):1533. doi: 10.3390/ph15121533.
2
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
J Acquir Immune Defic Syndr. 2020 May 1;84(1):70-77. doi: 10.1097/QAI.0000000000002294.
3
Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02213-16. Print 2017 Jun.
4
Raltegravir pharmacokinetics in neonates following maternal dosing.
J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316.
本文引用的文献
1
Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.
JAMA. 2011 Jul 6;306(1):70-8. doi: 10.1001/jama.2011.915.
2
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver.
Drug Metab Dispos. 2011 May;39(5):912-9. doi: 10.1124/dmd.110.037192. Epub 2011 Jan 25.
3
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
Clin Pharmacol Ther. 2008 Feb;83(2):293-9. doi: 10.1038/sj.clpt.6100281. Epub 2007 Aug 22.
4
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15. doi: 10.1097/QAI.0b013e31802b4956.
5
Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group.
Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):661-7. doi: 10.1053/ob.1996.v175.a75478.
Zotero 插件